Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.8%

1 terminated out of 55 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

7%

4 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (24)
Early P 1 (1)
P 1 (2)
P 2 (15)
P 3 (4)

Trial Status

Recruiting17
Active Not Recruiting12
Completed11
Not Yet Recruiting7
Unknown5
Withdrawn2

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (55)

Showing 20 of 20 trials
NCT05877859Recruiting

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT06727773Phase 2Recruiting

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

NCT06336538Not ApplicableActive Not Recruiting

Abbreviated MBCT for Depression in Older Black or African American Breast Cancer Survivors

NCT06926530Not Yet Recruiting

Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse Populations

NCT03927027Phase 3Active Not Recruiting

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT07218432Not ApplicableRecruiting

A Study of the TheraBionic P1 Device in Breast Cancer

NCT06721065Not ApplicableRecruiting

A Study of Language Interpretation Solutions for People With Breast Cancer

NCT03270072Active Not RecruitingPrimary

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

NCT07486687Phase 3Not Yet Recruiting

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

NCT06802172Not ApplicableRecruiting

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT03384914Phase 2Active Not Recruiting

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

NCT06268665Phase 2Recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT06806930Phase 2Recruiting

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

NCT05898789Not ApplicableRecruiting

Virtual Rehabilitation for Cancer Survivors

NCT05528263Not ApplicableCompleted

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

NCT07188246Phase 2Recruiting

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

NCT03766009Not ApplicableActive Not Recruiting

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

NCT03879577Phase 2Active Not Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

NCT06771635Not ApplicableCompleted

Effect of Physical Training Program on the Exercise Adherence for Breast Cancer Survivor

NCT07002177Phase 1Recruiting

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Scroll to load more

Research Network

Activity Timeline